Evolocumab approved for reducing LDL cholesterol

Am J Health Syst Pharm. 2015 Oct 1;72(19):1599-600. doi: 10.2146/news150066.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / therapeutic use*
  • Cholesterol, LDL / drug effects
  • Drug Approval
  • Humans
  • Hypercholesterolemia / drug therapy*
  • Hyperlipoproteinemia Type II / drug therapy
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • evolocumab